Drugs /

vt3989

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for vt3989

Vt3989 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating vt3989, 1 is phase 1 (1 open).

NF2 Loss and NF2 Mutation are the most frequent biomarker inclusion criteria for vt3989 clinical trials.

Malignant pleural mesothelioma and malignant solid tumor are the most common diseases being investigated in vt3989 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vt3989
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vt3989 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.